Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorpora… Read more
Market Cap & Net Worth: Spermosens AB (publ) (9R5)
Spermosens AB (publ) (F:9R5) has a market capitalization of $651.40K (€634.60K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #37406 globally and #4815 in its home market, demonstrating a -97.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spermosens AB (publ)'s stock price €0.00 by its total outstanding shares 3173024065 (3.17 Billion).
Spermosens AB (publ) Market Cap History: 2026 to 2026
Spermosens AB (publ)'s market capitalization history from 2026 to 2026. Data shows growth from $651.40K to $651.40K (0.00% CAGR).
Spermosens AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spermosens AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9R5 by Market Capitalization
Companies near Spermosens AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Spermosens AB (publ) by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Spermosens AB (publ) Historical Marketcap From 2026 to 2026
Between 2026 and today, Spermosens AB (publ)'s market cap moved from $651.40K to $ 651.40K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €651.40K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Spermosens AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $651.40K USD |
| MoneyControl | $651.40K USD |
| MarketWatch | $651.40K USD |
| marketcap.company | $651.40K USD |
| Reuters | $651.40K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.